Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir, Daclatasvir and Sofosbuvir in HCV Genotype 1
NCT02349048Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Primary completion
- Feb 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of simeprevir in hepatitis C (HCV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained Virologic Response at 12 Weeks. Started Jan 2015; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02349048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349048.